Metrics as of 10/17/2026, 08:26 AM (Berlin time), refresh in progress.
Trinity Biotech Stock
Trinity Biotech plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- Ireland
- CEO
- John Gillard
- Employees
- 287
- Market cap
- $163 M
- IPO
- 21/10/1992
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and…
Trinity Biotech stock: price history
1D
+1.3%
1W
+17.1%
1M
+14.2%
6M
-64.1%
YTD
-66.2%
1Y
-73.8%
2Y
-85.0%
5Y
-97.4%
10Y
-99.2%
Next earnings date
Next earnings date
10/12/2026 (in 54 days)
Volatility around earnings
~95% stronger price swings than usual
Trinity Biotech stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Trinity Biotech plc develops and distributes specialized medical diagnostic solutions for the global market. Its product portfolio comprises point-of-care systems and clinical laboratory tests for identifying various infectious diseases, including Lyme disease, sexually transmitted pathogens such as syphilis and herpes, and SARS-CoV-2. The company also offers reagents for diabetes monitoring and for diagnosing liver and kidney diseases. Distribution is carried out through its own sales team as well as a network of independent distributors and strategic partners serving clinical laboratories, research institutions, and public health authorities.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- Medium
- Customer concentration
- Unknown
Ask the agents about Trinity Biotech
Analyst assessment of Trinity Biotech
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 04/10/2016
Trinity Biotech stock metrics
P/E
-0.17
P/B
-0.07
EV/EBITDA
-66.08
RETURN ON EQUITY
24.3%
NET MARGIN
-157.8%
DEBT/EQUITY
-1.92
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
78.7%
FLOAT SHARES
796,446
AVG. DAILY VOLUME (30D)
14,453
Attention
Price since yesterday: +1.3%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Trinity Biotech stock
What does Trinity Biotech do?
Trinity Biotech plc is a company in the Healthcare sector, Medical - Specialties industry, headquartered in Ireland.
The CEO is John Gillard, the company employs around 287 people.
The IPO was on 21/10/1992; the stock trades on NASDAQ under the ticker TRIB.
What do analysts say about Trinity Biotech stock?
4 analysts rate the stock, the consensus is Buy (as of 04/10/2016).
This is an external assessment, not a statement by Market Jury.
When does Trinity Biotech report next?
The next earnings date is 10/12/2026.
Around past earnings, price swings were roughly 95% stronger than usual.
Does Trinity Biotech pay a dividend?
Yes. The last dividend was US$0.22 per share, ex-date 05/06/2015, paid on 01/07/2015.
The dividend yield is 0.0% (as of 31/12/2025).
Which stocks are comparable to Trinity Biotech?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Medtronic, Jazz Pharmaceuticals, Eli Lilly and Company and Johnson & Johnson.
How can I get Trinity Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Trinity Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.